



Course Directors

Petr Arenberger, Prague, Czech Republic
Claus Garbe, Tuebingen, Germany
Axel Hauschild, Kiel, Germany
Christoph Höller, Vienna, Austria

7TH EUROPEAN SCHOOL OF DERMATO-ONCOLOGY: UPDATE ON CUTANEOUS ONCOLOGY (ESDO)

JANUARY 17th-19th, 2019

NOVOTEL BERLIN AM TIERGARTEN
BERLIN, GERMANY



www.dermato-oncology2019.org

Preliminary Program
(update 21/09/2018)

Content

European Association of Dermato-Oncology (EADO)	2
Target Audience	2
Educational Objectives	2
Course Organization	3
Program Overview	4
Program	6
Thursday, January 17 th , 2019	6
Friday, January 18 th , 2019	7
Saturday, January 19 th , 2019	10
Course Faculty	11
General Information	14
Sponsors	17



European Association of Dermato-Oncology (EADO)

The EADO is a non-profit organization funded in 1999 to promote, coordinate and improve clinical and laboratory research activities in the field of skin cancer including primary and secondary prevention, early detection, clinical diagnosis and clinical and experimental research. EADO has organized many successful meetings and the upcoming ones are visible on the website (www.eado.org).

The EADO initiates for the sixth time a course dedicated to fundamentals in skin cancer targeted to specialists and residents in the final phase of their resident program. They will benefit a comprehensive and updated course to improve their decision-making process for the management of all types and stages of skin cancer, from diagnosis, primary treatment and adjuvant treatment, to the management of locoregional disease and distant metastatic disease.

Target Audience

This 2,5-day educational course targets doctors who are actively involved in the treatment of skin cancer. Dermatologists or other specialists who have completed specialist training, or residents in the final year of their training program, are likely to gain the most from this course.

Educational Objectives

The principal aim of the course is to provide a comprehensive and detailed understanding of the decision-making process for the management of all types and stages of skin cancer. This will include diagnosis and primary treatment, management of locoregional disease and distant metastatic disease, and adjuvant treatment. This is particularly relevant given the rapid progress in our understanding of melanoma and non-melanoma skin cancer, and the development of new treatments. In particular delegates will acquire the following knowledge:

1. Strategies for diagnosis of melanoma, Merkel cell and non-melanoma skin cancer including dermoscopy and confocal laser microscopy.
2. The indications, risks and benefits and strategies for mole screening.
3. Diagnosis of skin cancer: how to break bad news.
4. The indications and methods for genetic diagnosis and genetic counseling of skin cancer patients.
5. The present AJCC staging systems and how to stage melanoma, Merkel cell and cutaneous squamous cell carcinoma, and other non-melanoma skin cancers.

6. The value of imaging and biomarkers for the detection of metastases and disease staging.
7. Adjuvant treatment of skin cancer: radiotherapy, immunotherapy, chemotherapy.
8. New systemic treatments for stage IV melanoma: targeted agents and immunotherapeutics.
9. New treatment options of advanced basal cell carcinoma.
10. New systemic treatments for advanced Merkel cell and squamous cell carcinoma.
11. The characteristics of mucosal and uveal melanomas and their treatment options.
12. Options for topical treatment of epithelial skin cancers.
13. The current classification of cutaneous lymphoma, staging and treatment options for different subtypes of cutaneous lymphoma.
14. Clinical trials in skin cancer: an update.
15. The indications and strategies for supportive treatments including best supportive care.

Course Organization

The course consists of plenary sessions and interactive outbreak sessions. Plenary sessions will comprise clear structured and up-to-date presentations followed by audience discussion. Voting devices will be used to respond to multiple choice questions. These questions may precede the presentation of the structured knowledge or may be presented at the end in order to test the level of knowledge the audience has gained.

The main part of the course consists of 8 interactive sessions, each with no more than 30 attendants. Every participant takes part in each of these sessions which mainly comprise case-based discussion. These will be used to illustrate treatment pathways, how risk and benefit are assessed, and how management decisions are made.


We look forward to welcoming you in Berlin in January 2019!



Petr Arenberger, MD



Claus Garbe, MD



Axel Hauschild, MD



Christoph Höller, MD

Course Directors

Program Overview

A commercial exhibition will be held on all days close to the meeting rooms.

	8:00	9:00	10:00	11:00	12:00
Thursday January 17th, 2019					
Group I	Lectures: Kurland 2+3 Course A+E: Kurland 1 Course B+F: Kurland 2 Course C+G: Kurland 3 Course D+H: Berlin-Ceres All meeting rooms are located on the ground floor.				
Group II					
Group III					
Group IV					
Friday January 18th, 2019					
Group I	PLENARY SESSION 2 <i>C. Garbe A. Hauschild C. Höller C. Robert</i>	Break	COURSE C <i>C. Höller</i>	Break	COURSE D <i>C. Lebbé</i>
Group II		Break	COURSE D <i>C. Lebbé</i>	Break	COURSE A <i>R. Kaufmann</i>
Group III		Break	COURSE A <i>R. Kaufmann</i>	Break	COURSE B <i>A. Stratigos</i>
Group IV		Break	COURSE B <i>A. Stratigos</i>	Break	COURSE C <i>C. Höller</i>
Saturday January 19th, 2019					
Group I	COURSE G <i>F. Overkamp</i>	Break	COURSE H <i>R. Dummer</i>	Break	PLENARY SESSION 4 <i>M. Weichenthal L. K. Seculovic P. Arenberger I. Zalaudek</i>
Group II	COURSE H <i>R. Dummer</i>	Break	COURSE E <i>M. Volkenandt</i>	Break	
Group III	COURSE E <i>M. Volkenandt</i>	Break	COURSE F <i>C. Garbe</i>	Break	
Group IV	COURSE F <i>C. Garbe</i>	Break	COURSE G <i>F. Overkamp</i>	Break	

13:00	14:00	15:00	16:00	17:00	18:00
	Welcome Session	PLENARY SESSION 1 <i>J.J. Grob</i> <i>P. Mohr</i> <i>M. Arenbergerova</i> <i>I. Zalaudek</i>	Break	COURSE A <i>R. Kaufmann</i>	COURSE B <i>A. Stratigos</i>
			COURSE B <i>A. Stratigos</i>	Break	COURSE C <i>C. Höller</i>
			COURSE C <i>C. Höller</i>		COURSE D <i>C. Lebbé</i>
			COURSE D <i>C. Lebbé</i>		COURSE A <i>R. Kaufmann</i>
PLENARY SESSION 3 <i>J. Malvehy</i> <i>P. Arenberger</i> <i>S. P. Sarda</i> <i>L. Thomas</i>		Break	COURSE E <i>M. Volkenandt</i>	COURSE F <i>C. Garbe</i>	
			COURSE F <i>C. Garbe</i>	Break	COURSE G <i>F. Overkamp</i>
			COURSE G <i>F. Overkamp</i>	Break	COURSE H <i>R. DUMMER</i>
			COURSE H <i>R. DUMMER</i>		COURSE E <i>M. Volkenandt</i>
	EXAMINATIONS: EUROPEAN CERTIFICATE FOR MEDICAL TUMOR THERAPY IN DERMATOONCOLOGY				

Program

Thursday, January 17th, 2019

13:45-14:00	Welcome and course introduction <i>Claus Garbe, Tuebingen, Germany</i>
PLENARY SESSION 1: Screening and early detection <i>Chairperson: Ana Maria Forsea and Monika Arenbergerova</i>	
14:00-14:20 Kurland 2+3	LECTURE 1: Epidemiology of skin cancer <i>Jean Jacques Grob, Marseille, France</i>
14:20-14:40 Kurland 2+3	LECTURE 2: Skin cancer screening: Fact or fiction <i>Peter Mohr, Buxtehude, Germany</i>
14:40-15:00 Kurland 2+3	LECTURE 3: Dermoscopy of melanocytic skin cancers (with quiz questions) <i>Monika Arenbergerova, Prague, Czech Republic</i>
15:00-15:20 Kurland 2+3	LECTURE 4: Dermoscopy of non-melanocytic skin cancers (with quiz questions) <i>Iris Zalaudek, Trieste, Italy</i>
15:20-15:30	Discussion
15:30-16:00	Coffee Break
16:00-17:00 Group I Kurland 1	COURSE A: Paraneoplastic syndromes <i>Roland Kaufmann, Frankfurt, Germany</i>
16:00-17:00 Group II Kurland 2	COURSE B: Treatment of actinic keratosis and field cancerization <i>Alexander Stratigos, Athens, Greece</i>
16:00-17:00 Group III Kurland 3	COURSE C: Intralesional tumor treatments <i>Christoph Höller, Vienna, Austria</i>
16:00-17:00 Group IV Berlin-Ceres	COURSE D: Common and rare adverse events of checkpoints inhibitors and targeted therapies <i>Celeste Lebbé, Paris, France</i>
17:00-17:30	Coffee Break

17:30-18:30 Group I Kurland 2	COURSE B: Treatment of actinic keratosis and field cancerization <i>Alexander Stratigos, Athens, Greece</i>
17:30-18:30 Group II Kurland 3	COURSE C: Intralesional tumor treatments <i>Christoph Höller, Vienna, Austria</i>
17:30-18:30 Group III Berlin-Ceres	COURSE D: Common and rare adverse events of checkpoints inhibitors and targeted therapies <i>Celeste Lebbé, Paris, France</i>
17:30-18:30 Group IV Kurland 1	COURSE A: Paraneoplastic syndromes <i>Roland Kaufmann, Frankfurt, Germany</i>

Friday, January 18th, 2019

	PLENARY SESSION 2: Guidelines for melanoma management and case discussions <i>Chairperson: Roland Kaufmann and Christoph Höller</i>
08:00-08:20 Kurland 2+3	LECTURE 5: Mutational testing <i>Claus Garbe, Tuebingen, Germany</i>
08:20-08:40 Kurland 2+3	LECTURE 6: Adjuvant therapies for high risk melanoma <i>Axel Hauschild, Kiel, Germany</i>
08:40-09:00 Kurland 2+3	LECTURE 7: Targeted therapy of metastatic melanoma <i>Christoph Höller, Vienna, Austria</i>
09:00-09:20 Kurland 2+3	LECTURE 8: Immune checkpoint inhibition <i>Caroline Robert, Paris, France</i>
09:20-09:30	Discussion

09:30-10:00	Coffee Break
10:00-11:00	COURSE C: Intralesional tumor treatments <i>Christoph Höller, Vienna, Austria</i>
Group I Kurland 3	
10:00-11:00	COURSE D: Common and rare adverse events of checkpoints inhibitors and targeted therapies <i>Celeste Lebbé, Paris, France</i>
Group II Berlin-Ceres	
10:00-11:00	COURSE A: Paraneoplastic syndromes <i>Roland Kaufmann, Frankfurt, Germany</i>
Group III Kurland 1	
10:00-11:00	COURSE B: Treatment of actinic keratosis and field cancerization <i>Alexander Stratigos, Athens, Greece</i>
Group IV Kurland 2	
11:00-11:30	Coffee Break
11:30-12:30	COURSE D: Common and rare adverse events of checkpoints inhibitors and targeted therapies <i>Celeste Lebbé, Paris, France</i>
Group I Berlin-Ceres	
11:30-12:30	COURSE A: Paraneoplastic syndromes <i>Roland Kaufmann, Frankfurt, Germany</i>
Group II Kurland 1	
11:30-12:30	COURSE B: Treatment of actinic keratosis and field cancerization <i>Alexander Stratigos, Athens, Greece</i>
Group III Kurland 2	
11:30-12:30	COURSE C: Intralesional tumor treatments <i>Christoph Höller, Vienna, Austria</i>
Group IV Kurland 3	
12:30-13:00	Lunch
PLENARY SESSION 3: Melanoma diagnostics and follow-up <i>Chairperson: Susanna Puig and Petr Arenberger</i>	
13:00-13:30	LECTURE 9: New diagnostic devices <i>Josep Malvehy, Barcelona, Spain</i>
Kurland 2+3	
13:30-14:00	LECTURE 10: Follow-up of melanoma and non-melanoma skin cancer <i>Petr Arenberger, Prague, Czech Republic</i>
Kurland 2+3	

14:00-14:30 Kurland 2+3	LECTURE 11: Dermoscopy of facial lesions <i>Susana Puig Sardá, Barcelona, Spain</i>
14:30-15:00 Kurland 2+3	LECTURE 12: Dermoscopy of acral lesions <i>Luc Thomas, Lyon, France</i>
15:00-15:30	Coffee Break
15:30-16:30 Group I Kurland 1	COURSE E: Systemic treatment of non-melanoma skin cancer <i>Axel Hauschild, Kiel, Germany</i>
15:30-16:30 Group II Kurland 2	COURSE F: Excisional, incisional and shave biopsies: How I do it <i>Claus Garbe, Tuebingen, Germany</i>
15:30-16:30 Group III Kurland 3	COURSE G: The new oncologic drugs: their mode of action <i>Olivier Michielin, Lausanne, Switzerland</i>
15:30-16:30 Group IV Berlin-Ceres	COURSE H: Cutaneous lymphomas <i>Emmanuela Guenova, Zurich, Switzerland</i>
16:30-16:45	Coffee Break
16:45-17:45 Group I Kurland 2	COURSE F: Excisional, incisional and shave biopsies: How I do it <i>Claus Garbe, Tuebingen, Germany</i>
16:45-17:45 Group II Kurland 3	COURSE G: The new oncologic drugs: their mode of action <i>Olivier Michielin, Lausanne, Switzerland</i>
16:45-17:45 Group III Berlin-Ceres	COURSE H: Cutaneous lymphomas <i>Emmanuela Guenova, Zurich, Switzerland</i>
16:45-17:45 Group IV Kurland 1	COURSE E: Systemic treatment of non-melanoma skin cancer <i>Axel Hauschild, Kiel, Germany</i>

Saturday, January 19th, 2019

08:30-09:30	COURSE G: The new oncologic drugs: their mode of action <i>Olivier Michielin, Lausanne, Switzerland</i>
Group I Kurland 3	
08:30-09:30	COURSE H: Cutaneous lymphomas <i>Emmanuela Guenova, Zurich, Switzerland</i>
Group II Berlin-Ceres	
08:30-09:30	COURSE E: Systemic treatment of non-melanoma skin cancer <i>Axel Hauschild, Kiel, Germany</i>
Group III Kurland 1	
08:30-09:30	COURSE F: Excisional, incisional and shave biopsies: How I do it <i>Claus Garbe, Tuebingen, Germany</i>
Group IV Kurland 2	
09:30-10:00	Coffee Break
10:00-11:00	COURSE H: Cutaneous lymphomas <i>Emmanuela Guenova, Zurich, Switzerland</i>
Group I Berlin-Ceres	
10:00-11:00	COURSE E: Systemic treatment of non-melanoma skin cancer <i>Axel Hauschild, Kiel, Germany</i>
Group II Kurland 1	
10:00-11:00	COURSE F: Excisional, incisional and shave biopsies: How I do it <i>Claus Garbe, Tuebingen, Germany</i>
Group III Kurland 2	
10:00-11:00	COURSE G: The new oncologic drugs: their mode of action <i>Olivier Michielin, Lausanne, Switzerland</i>
Group IV Kurland 3	
11:00-11:30	Coffee Break
PLENARY SESSION 4: HOT TOPICS IN DERMATOONCOLOGY <i>Chairperson: Lidija Kandolf Sekulovic and Iris Zalaudek</i>	
11:30-12:00	LECTURE 13: The new AJCC classification for melanoma 2018 <i>Michael Weichenthal, Kiel, Germany</i>
Kurland 2+3	
12:00-12:30	LECTURE 14: Management of mucosal and ocular melanomas <i>Lidija Kandolf Sekulovic, Belgrade, Serbia</i>
Kurland 2+3	
12:30-13:00	LECTURE 15: Rare skin cancers: interactive quiz <i>Petr Arenberger, Prague, Czech Republic</i>
Kurland 2+3	
13:00-13:30	LECTURE 16: Dermoscopy Quiz <i>Iris Zalaudek, Trieste, Italy</i>
Kurland 2+3	
13:30-14:00	Lunchbags
14:00-17:00	Examinations: European Certificate for Medical Tumor Therapy in Dermatoonology

Invited Course Faculty

A

Petr Arenberger, MD

Professor of Dermatology, Director
Department of Dermatology
Charles University
3rd School of Medicine
Srobarova 50
CZ-100 34 Prague, Czech Republic
Phone: +420-26716-3000
Email: avemedita@email.cz

Monika Arenbergerova, MD

Department of Dermatovenereology,
Third Faculty of Medicine
Charles University in Prague
Czech Republic
Email: arenbergerova(a)email.cz

F

Ana-Maria Forsea, MD

Assistant Professor for Dermatology
Department of Dermatology
Carol Davila University of Medicine
and Pharmacy Bucharest
Bulevardul Eroii Sanitari 8
050474 Bucharest, Romania
Phone: +40-21-3180462
Email: aforsea@yahoo.com

G

Claus Garbe, MD

Professor of Dermatology
Department of Dermatology
Eberhard Karls University
Liebermeister Str. 25
72076 Tuebingen, Germany
Phone: +49-7071-2987110
Email: claus.garbe@med.uni-tuebingen.de

Jean Jacques Grob, MD

Professor of Dermatology
Service de Dermatology and
Cancer Research
Hôpital de la Timone
264 Rue St. Pierre
13005 Marseille, France
Phone: +33-491-388591
Email: jean-jacques.grob@ap-hm.fr

Emmanuela Guenova, MD

Department of Dermatology
University of Zurich
Hospital
Gloriastrasse 31
8091 Zurich
Switzerland
Phone: +41-442552507
Email: Emmanuella.Guenova@usz.ch

H**Axel Hauschild, MD**

Professor of Dermatology
 Department of Dermatology
 University of Kiel
 Rosalind-Franklin-Str. 7
 24105 Kiel, Germany
 Phone: +49-431-50021131
 Email: ahauschild@dermatology.uni-kiel.de

Christoph Höller, MD

Professor of Dermatology
 Department of Dermatology
 Medical University of Vienna
 Waehringer Guertel 18-20
 1090 Vienna, Austria
 Phone: +43-1-404004786
 Email: christoph.hoeller@meduniwien.ac.at

K**Lidija Kandolf Sekulovic, MD**

Professor of Dermatology
 Department of Dermatology
 Medical Faculty
 Military Medical Academy
 Crnotravska 17
 11000 Belgrade, Serbia
 Phone: +381-11-3608583
 Email: lkandolfsekulovic@gmail.com

Roland Kaufmann, MD

Professor of Dermatology, Director
 Department of Dermatology
 Clinical Center J. W. Goethe University
 Theodor-Stern-Kai 7
 60590 Frankfurt/Main, Germany
 Phone: +49-69-63015311
 Email: kaufmann@em.uni-frankfurt.de

L**Celeste Lebbé, MD**

Professor of Dermatology
 Department of Dermatology
 Hôpital Saint-Louis
 1, Avenue Claude-Vellefaux
 75010 Paris, France
 Phone: +33-142494679
 Email: celeste.lebbe@aphp.fr

M**Josep Malvehy, MD**

Director of the Melanoma Unit
 Department of Dermatology
 Hospital Clinic of Barcelona
 C/Villarroel 170
 08036 Barcelona, Spain
 Phone: +34-933638920
 Email: jmalvehy@clinic.ub.es

Olivier Michielin, MD

Head of Melanoma Clinic
 Department of Oncology
 Swiss Institute of Bioinformatics
 Ludwig Institute
 1015 Lausanne
 Switzerland
 Phone: +41-21-692-4053
 Email: Olivier.Michielin@chuv.ch

Peter Mohr, MD

Center of Dermatology
 Elbe Klinikum Buxtehude
 Am Krankenhaus 1
 21614 Buxtehude
 Germany
 Phone: +49-4161-7036209/-6250
 Email: peter.mohr@elbekliniken.de

P***Susana Puig Sardá, MD***

Department of Dermatology
Hospital Clinic of Barcelona
C/Villarroel 170
Barcelona, Spain
Phone: +34-933638920
Email: susipuig@gmail.com

R***Caroline Robert, MD***

Head Dermatology
Gustave Roussy Institute
114 rue Edouard Vaillant
94801 Villejuif, France
Phone: +33-1-4211-6497
Email: caroline.robert@gustaveroussy.fr

S***Alexander Stratigos, MD***

Department of Dermatology
University of Athens
School of Medicine
Andreas Sygros Hospital
5 Dragoumi Street
Athens 161 21, Greece
Phone: +30-210-7231731
Email: alstrat2@gmail.com

T***Luc Thomas, MD***

Department of Dermatology
Centre hospitalier Lyon sud
165 Chemin DU GRAND REVOYET
69310 - PIERRE-BENITE
Email: luc.thomas@chu-lyon.fr

W***Michael Weichenthal, MD***

Professor of Dermatology
Department of Dermatology
University of Kiel
Rosalind-Franklin-Str. 7
24105 Kiel, Germany
Phone: +49-431-500-21141
Email: mweichenthal@dermatology.
uni-kiel.de

Z***Iris Zalaudek, MD***

Head of the Dermatology Clinic
University of Trieste
Hospital Maggiore
Piazza dell' Ospedale 1
34125 Trieste, Italy
Email: iris.zalaudek@gmail.com

General Information

Cancellation Policy

Cancellations must be received in writing by December 20, 2018. No refunds will be granted after that date. A processing fee of 30 Euro will be deducted from each cancelled registration. Substitutions are possible. To substitute a registration, please send an email including the name of the original registrant and the name of the person substituting to info@medconcept.org.

The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by force, or should the non-appearance of speakers or other reasons need program changes. With registration, the participant accepts this proviso.

CME Credits

An application for CME accreditation will be made.

How to receive your CME Credits

To obtain CME credits, please fill in the evaluation forms, which you will find in your course bag. To get your certificate of attendance with the CME credits please return the evaluation forms duly filled in to the registration desk.

Course Organization

MEDCONCEPT 

MedConcept Gesellschaft für medizinische Projekte mbH
Friedenstraße 58
15366 Neuenhagen b. Berlin, Germany
Phone: +49 (0)3342 42689-30
Fax: +49 (0)3342 42689-40
E-Mail: info@medconcept.org
www.medconcept.org

Course Venue

Novotel Berlin am Tiergarten

Strasse des 17. Juni 106

10623 Berlin, Germany

Phone: +49 (0)30 600350

E-Mail: H3649-SB@accor.com

<http://www.novotel.com/gb/hotel-3649-novotel-berlin-am-tiergarten/index.shtml>

European Certificate for Medical Tumor Therapy in Dermatooncology

Definition: The advanced continuing medical education training in “Medical Tumor Therapy in Dermatooncology” is intended as an addition to the specialist dermatologist’s competence, and covers the administration and monitoring of medical therapy of patients with malignant skin tumors, including supportive measures and management of complications and side-effects from therapy.

Training Goal: The aim of the continuing education training program is to obtain the professional competence in systemic therapy for skin cancers after completing the required training period. The competence will be certified by the **European Certificate for Medical Tumor Therapy in Dermatooncology** awarded by EADO in collaboration with UEMS.

Prerequisites for candidates:

- Certification of specialist in dermatology by the relevant national authority (Board Certification)
- Completion of training program (12 months involved in direct patients care)
- Attendance of at least one ESDO course
- Examination by the EADO Board Certification in Dermato-Oncology

For further information please contact Mr. Christopher Huhn at christopher.huhn@med-concept.org.

Exhibition Opening Hours

Thursday, January 17: 13:00-18:30

Friday, January 18: 07:30-18:00

Saturday, January 19: 08:00-13:30

Fees

Registration Fee of **380 Euro (incl. VAT)** covers

- Admission to scientific sessions
- Admission to exhibition
- Bag with course documents
- Welcome reception
- Coffee breaks and lunch
- Certificate of attendance

Language and Translation

The official language of the meeting will be English. Simultaneous translation will not be provided.

Registration/Information Desk

The registration desk is situated at the ground floor of the Novotel Berlin am Tiergarten.

Opening hours

Thursday, January 17: 12:00-19:00

Friday, January 18: 07:30-18:00

Saturday, January 19: 08:00-14:00

Sustainability

MedConcept is internally working on increasing its sustainability efforts and we would like to encourage all involved in the 7th European School of Dermato-Oncology Meeting to minimize their environmental and social impacts.

Ways to get involved:

- Travel by train or carbon offsetting your flights to Berlin and encourage your colleagues to do the same
- If travelling by car, car pool with your colleagues
- Use the recycling bins provided on-site
- Recycle your name-badge in the bin provided at the registration desk
- Recycle all brochures and promotional items not needed in the bin provided within the industrial exhibition
- Use the public transportation system in Berlin

Sponsors

SILVER SPONSOR



BRONZE SPONSORS

The Merck logo, consisting of the word "MERCK" in a bold, purple, sans-serif font.The Sanofi Genzyme logo, with "SANOFI" in a gold sans-serif font and "GENZYME" in a blue sans-serif font, followed by a small circular icon with a blue and green gradient.

FURTHER SPONSORS



Registration Form

7th European School of Dermato-Oncology

January 17th-19th, 2019
Novotel Berlin am Tiergarten
Berlin, Germany

First Name: _____ Last Name: _____

Professional Title: _____ Degree: MD PhD RN PA-C

Gender: Male Female Speciality: _____

Institution: _____ Address: _____

City: _____ Zip Code: _____ Country: _____

Phone: _____ Fax: _____ E-Mail: _____

Fees

Registration Fee of **380,00 Euro** (incl. VAT) covers

- Admission to scientific sessions
- Admission to exhibition
- Bag with course documents
- Welcome reception
- Coffee breaks and lunch
- Certificate of Attendance

Payment Method

Bank Transfer: Registration can only be confirmed upon receipt of full payment.

Credit Card: MasterCard Visa American Express

Credit Card Number: _____

Expiration Date: _____

Security Code CCV: _____ (MC/Visa - 3 digits on back, AMEX - 4 digits on front)

Cardholder Name: _____

Signature: _____

An invoice will be send by email to the given address. If the invoice address is different from the address given above, please send an email including the name of the registrant and the full invoice address to christopher.huhn@medconcept.org.

By completing the registration form, the participant accepts the general terms and conditions as well as the cancellation policy given on the congress website at www.melanomaglobal2019.org and agrees that his/her data may be used, processed and published (e.g. within the list of participants) for organizational purposes of the event. The participant accepts that MedConcept will contact him/her by email for organizational matters (e.g. the registration confirmation and invoice) and information related to the event.

I accept until further notice that MedConcept will inform me about future events by email.

To Register

Mail registration form to:

MedConcept GmbH, Friedenstraße 58, 15366 Neuenhagen bei Berlin, Germany

Fax registration form to: +49 (0)3342 42689-40

Register online: www.dermato-oncology2019.org